Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Many of the population suffer from allergies, frequently associated with a low quality of life characterized by the constant fear of...
-
ATHENS, Greece, Dec. 12, 2024 (GLOBE NEWSWIRE) -- FAAM-EUROBAT 2024, held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share...
-
On 21 November 2024, during the opening day of EAACI FAAM-EUROBAT 2024 in Athens, Greece, EAACI proudly launches World Anaphylaxis Day. Join us!
-
Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.
-
The European Academy of Allergy and Clinical Immunology (EAACI) has released updated "Clinical Guidelines on the Management of IgE-mediated Food Allergy."
-
Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Food Allergy Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Allergen Source, Treatment Type, Channel, Region, By...
-
Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.
-
Wilmington, Delaware, United States, Transparency Market Research, Inc., Sept. 05, 2024 (GLOBE NEWSWIRE) -- The projected allergy treatment market (알레르기 치료 시장) growth will drive the market to reach...
-
Insignis’ liquid epinephrine sublingual spray for anaphylaxis, stable and usable under both extreme heat and cold, gains FDA Fast Track designation.
-
Dublin, Aug. 06, 2024 (GLOBE NEWSWIRE) -- The "United States Food Allergen Testing Market Forecast Report By Food Testing, Technology, States and company analysis 2024-2032" report has been added to...